Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations

Oncogene

Volumn 32, Issue 18, 2013, Pages 2346-2355

  Furcht, C M ^a   Munoz Rojas A R ^a   Nihalani, D ^b   Lazzara, M J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

endocytosis; extracellular signal regulated kinase (ERK); gefitinib; GRB2 associated binder 1 (GAB1)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN GRB2 ASSOCIATED BINDER 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL COMPARTMENTALIZATION; CELL MEMBRANE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFECT; ENDOCYTOSIS; ENZYME ACTIVITY; GENE MUTATION; IC 50; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL MEMBRANE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; HUMANS; LUNG NEOPLASMS; MUTATION; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84877575295     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.240     Document Type: Article

References (31)

1. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139.
2. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-1167.
3. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21: 2237-2246.
4. Akca H, Tani M, Hishida T, Matsumoto S, Yokota J. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. Lung Cancer 2006; 54: 25-33.
5. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 2005; 102: 3788-3793.
6. Guo A, Villen J, Kornhauser J, Lee KA, Stokes MP, Rikova K et al. Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci USA 2008; 105: 692-697.
7. Lazzara MJ, Lane K, Chan R, Jasper PJ, Yaffe MB, Sorger PK et al. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res 2010; 70: 3843-3850.
8. Neel BG, Gu H, Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 2003; 28: 284-293.
9. Araki T, Nawa H, Neel BG. Tyrosyl phosphorylation of Shp2 is required for normal ERK activation in response to some, but not all, growth factors. J Biol Chem 2003; 278: 41677-41684.
10. Gu H, Neel BG. The "Gab" in signal transduction. Trends Cell Biol 2003; 13: 122-130.
11. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-354.
12. Shi ZQ, Yu DH, Park M, Marshall M, Feng GS. Molecular mechanism for the Shp-2 tyrosine phosphatase function in promoting growth factor stimulation of Erk activity. Mol Cell Biol 2000; 20: 1526-1536.
13. Chan G, Kalaitzidis D, Neel BG. The tyrosine phosphatase Shp2 (PTPN11) in cancer. Cancer Metastasis Rev 2008; 27: 179-192.
14. Kontaridis MI, Swanson KD, David FS, Barford D, Neel BG. PTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effects. J Biol Chem 2006; 281: 6785-6792.
15. Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 2004; 64: 8816-8820.
16. Vieira AV, Lamaze C, Schmid SL. Control of EGF receptor signaling by clathrinmediated endocytosis. Science 1996; 274: 2086-2089.
17. Hendriks BS, Griffiths GJ, Benson R, Kenyon D, Lazzara M, Swinton J et al. Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. Syst Biol (Stevenage) 2006; 153: 457-466.
18. Salvi M, Stringaro A, Brunati AM, Agostinelli E, Arancia G, Clari G et al. Tyrosine phosphatase activity in mitochondria: presence of Shp-2 phosphatase in mitochondria. Cell Mol Life Sci 2004; 61: 2393-2404.
19. Maroun CR, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signalregulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 2000; 20: 8513-8525.
20. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 2010; 17: 77-88.
21. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008; 68: 9479-9487.
22. Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C et al. Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines. Mol Cancer Res 2006; 4: 521-528.
23. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 2006; 10: 25-38.
24. Offterdinger M, Bastiaens PI. Prolonged EGFR signaling by ERBB2-mediated sequestration at the plasma membrane. Traffic 2008; 9: 147-155.
25. Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D. Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. Cancer Res 2003; 63: 1130-1137.
26. Zhou X, Agazie YM. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. J Biol Chem 2009; 284: 12226-12234.
27. Paulsen CE, Truong TH, Garcia FJ, Homann A, Gupta V, Leonard SE et al. Peroxidedependent sulfenylation of the EGFR catalytic site enhances kinase activity. Nat Chem Biol 2011; 8: 57-64.
28. Ren Y, Chen Z, Chen L, Fang B, Win-Piazza H, Haura E et al. Critical role of Shp2 in tumor growth involving regulation of c-Myc. Genes Cancer 2010; 1: 994-1007.
29. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007; 7: 169-181.
30. Ventura A, Meissner A, Dillon CP, McManus M, Sharp PA, Van Parijs L et al. Cre-loxregulated conditional RNA interference from transgenes. Proc Natl Acad Sci USA 2004; 101: 10380-10385.
31. Wickrema A, Uddin S, Sharma A, Chen F, Alsayed Y, Ahmad S et al. Engagement of Gab1 and Gab2 in erythropoietin signaling. J Biol Chem 1999; 274: 24469-24474.